Analysis of an Age Related Topic
NSG4067. Microsoft word document of 6 pages in APA 7th edition. Conduct an in-depth analysis of a pertinent topic related to aging. Include the following in your analysis:
1. define the problem
2. identify the specific population affected.
3. describe cultural implications.
4. describe financial/legal/ethical implications for the population related to the problem.
5. describe 2-3 interventions that can be used to improve the problem.
6. describe resources available to improve the problem.
7. describe costs associated with the interventions identified.
8. discuss the sustainability of the interventions.
9. support your examples with responses.
Analysis of an Age Related Topic
An Age Related Topic
Course Name and Number
An Age Related Topic
As individuals advance in age, their physical and mental capacity decreases, increasing their vulnerability to diseases and finally leading to death. Empirically, physical activity decreases at an average 40-80% rate as one advances in age. Social and psychological elements play an essential role in influencing the process of aging and one’s overall sense of well-being. The term “normal ageing” refers not to the absence of sickness or financial well-being but rather to the optimal moral, social, and health processes that support one to respond positively to the ageing process, rather than the absence of disorder or economic well-being. Alzheimer’s disease is a problem associated with aging. This paper aims to investigate Alzheimer’s disease, which is linked to aging, in greater detail.
The Problem Statement
Alzheimer’s disease (AD) is a degenerative brain disorder that Age-related decline in cognitive abilities such as judgment, planning, and memory. Human brain cells die and degenerate as a consequence of Alzheimer’s disease, which normally starts slowly but eventually progresses. Having Alzheimer’s damages a person’s social, behavioral, and cognitive skills, which makes it difficult for them to operate independently. Forgetfulness sets in slowly and worsens with time, making it difficult to carry on normal daily tasks for individuals of all ages. Approximately sixty to eighty percent of all dementia cases are as a result of Alzheimer’s disease, according to study. This illness is also the sixth leading cause of demise in the United States. Alzheimer’s patients may typically anticipate a life expectancy of four to eight years. According to Alzheimer’s Association (Alzheimer’s Association, 2017), this might vary based on other circumstances.
Alzheimer’s disease primarily attacks the aged because it is usually detected after 65 years, when the condition is most common. When identified before 65 years, Alzheimer’s disease is referred to as early onset of Alzheimer’s disease. Since most of those spotted with Alzheimer’s disease are older persons over the age of 65, growing older has been discovered to be an essential risk factor for this disease, even though it is not a normal part of aging. The brain, like all other body parts, ages with time. As individuals get older, most people experience slow thinking and memory loss. Alzheimer’s disorder victims show a decline in their memory and confusion as they become older due to the descent of brain cells.
However, the elderly aren’t the only ones afflicted by the disease; young people are as well. Many people under 65 are diagnosed with early-onset Alzheimer’s disease, affecting roughly 200,000 Americans. Individuals diagnosed with early-stage Alzheimer’s disease have some memory loss, but after a number of years, the illness aggravates to the point that a person is unable to engage in a conversation precisely. According to the Alzheimer’s Association, over five million U.S citizens of over 65 years have been confirmed with Alzheimer’s disease (AD). By 2050, that figure is predicted to rise to even more than fifteen million people.
Cultural factors including group intellect, family, food, belief, and communication all play a part in how well persons with illnesses like Alzheimer’s and Parkinson’s disease fare in life and how well they receive treatment. Individuals with this disease benefit greatly from caregivers who have a deep understanding of their own culture. Alzheimer’s disease (AD) is a natural part of age advancement, according to Chinese and Hispanic health care professionals. This belief in Alzheimer’s disease (AD) may have an impact on the disease’s regulatory oversight and re-management. In addition, a person’s therapeutic treatment is concealed in many cultures. Rather than enlisting the assistance of loved ones to help with the supply of personal affection and care, this approach only relies on specialized care providers.
Financial, Legal or Ethical Implications
The inherent risks burden that AD places on society is that it is costly to families, healthcare providers, and the federal government. The direct expenses of Alzheimer’s disease are depicted to be massive. Alzheimer’s disease is expected to be the costliest ailment to treat in the US. by 2016, with an estimated cost of $235 billion. This indicates that the illness is tough to manage and expensive to cure. As a side effect, Alzheimer’s disease has caused significant financial hardship for many families. Family caregivers spend an estimated 18 billion hours take care for a treasured person with Alzheimer’s disease (Alzheimer’s Association, 2017).
Legal ramifications of Alzheimer’s disease are a major concern for the majority of individuals. Fundamental documentations for instance a will and advance directives may be modified when a person suffers from Alzheimer’s disease. As a result, people with the condition should be given legal guidance because they gradually lose their ability to think coherently (Preston et al.,2016). People with early-stage AD, on the other hand, can understand a variety of legal decision-making features and ramifications. It’s recommended that these individuals hire a lawyer to help them plan paperwork and interpret state legislation, and to advise them properly.
Additionally, the care and management of Alzheimer’s disease (AD) raises ethical concerns. Even if a family member decides to keep information from the patient because they fear it may distress him or her further in the end stages of Alzheimer’s disease, this possibly will have an ethical repercussion. An additional ethical quest is whether or not psychiatrists should begin limiting the driving privileges of Alzheimer’s disease patients.
There is no remedy for Alzheimer’s disease, although there are therapies that can defer its progression. It is also possible to enhance a person’s quality of life through the therapies (Graham, Bonito-Oliva, & Sakmar, 2017). There are presently no treatments that will arrest the development of the disorder, although they can alleviate the indicators. Although it gives the impression that handling and intervening in AD at an early stage saves finances, the difficulty is that many people are only identified after it is too late. As a result, timely intervention is critical since it has the potential to have a huge impact on the budget of therapy for Alzheimer’s disease.
Alzheimer’s disease treatment and cure research, on the other hand, is now happening in an effort to discover better and more successful treatments. Dementia-linked cognitive memory loss may now be more readily diagnosed thanks to advances in technology. In the battle against the illness, this is a key initial step. Patients with spartan Alzheimer’s disease may also be treated with non-pharmacological or pharmacological therapies. Drugs can be used in some circumstances to relax the advancement of Alzheimer’s disease in the short-run. These anti-dementia medications are supposed to be prescribed only by a doctor because they are based on a patient’s specific form of dementia. Acetylcholine inhibitors, for example, are used to treat Alzheimer’s disease by increasing levels of acetylcholine, a neurotransmitter found in abundance in the brain, and aids in nerve cell communication (Christiansen, 2018). Patients with slight dementia can profit from Cognitive Stimulation Therapy (CST), a non-pharmacological therapy for Alzheimer’s disease. Individual victims of Alzheimer’s disease benefit from therapeutic sessions planned by a professional practitioner who has expertise in interpersonal interaction and care planning (Duan, Lu, Chen, Liang, Zheng &Tang, 2018). Reminiscence therapy, another non-pharmacological treatment option, includes assisting individuals with dementia in regaining access to their memories in long-run.
Individuals with Alzheimer’s disease (AD) have a wealth of amenities and information at their disposal. There appears to be a wide range of state, not-for-profit, and specialized services geared at AD victims. Online resources for Alzheimer’s disease include the Dementia Caregiver Center, Community Resource Finder (Napoletan, 2017), the Alzheimer’s and Big List of Alzheimer’s Resources, and the Caregiver Space. Additionally, the Alzheimer’s Association provides many courses and facilities to assist personalities deal with and cope with their illness. Patients have access to a free, round-the-clock hotline where they may get emotional support, sound guidance, and dependable data (Napoletan, 2017).
The Alzheimer’s Association maintains regional headquarters in all states. Another option for persons with Alzheimer’s disease (AD) is to seek out local services and initiatives that can educate and empower them early on in the disease. The support programs and persons with the disease are able to connect with others who have the same condition so that they may learn from each other (Napoletan, 2017). Programs for persons in the early phases of the disease link them with one another and organize activities such as sporting events that gather many of them together.
Alzheimer’s disease is exceedingly expensive in terms of both direct and indirect costs. According to the Alzheimer’s Association, the disease’s overall cost was predicted to be $236 billion in the United States in 2016 (Alzheimer’s Association, 2017). Alzheimer’s disease (AD) accounted for $277 billion in direct expenses to the American economy in 2018. Alzheimer’s victims require $286,000 in handling and maintenance likened to $174,000 for individuals with cardiac diseases and malignance in 2010 (Alzheimer’s Association, 2018). Medicaid and Medicare endures the greater part of the expenditures associated with Alzheimer’s disease (AD). The disease and other dementias accounted for sixty-seven percent of the $186 billion in Medicaid and Medicare spending in 2015. According to the Alzheimer’s Association (2018), 1 in 5 Medicare expenditures is spent on a person with the disease.
Patients with Alzheimer’s disease have shown an improvement in their value of life as a product of treatment and management (Mayo Clinic Staff, 2018). While medication for Alzheimer’s doesn’t exist, there are means to keep the illness under control and enable those with it live up to an additional 20 years. Good food will improve the lives of many residents in nursing homes who are suffering from dementia. This will aid with the recuperation process and encourage appropriate nutrition by improving the environment. In the end, the eating setting should serve as a facilitator and be able to adapt to the changing requirements of residents as their cognitive disabilities progress. Most occupational therapists don’t do routine clinical assessments of factors such as the environment, lighting, noise, and how the staff takes care of their patients. Long-term care patients with dementia who are unable to function to their full potential or have “demeanor difficulties” may react to unhelpful stimuli in the environment. Aside from this fact, new therapeutic options for the condition are being researched.
Alzheimer’s Association. (2017). 2017 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia, 13(4), 325-373.
Alzheimer’s Association. (2018, March). Costs of Alzheimer’s to Medicare and Medicaid.
Retrieved February 1, 2019, from
Christiansen, S. (2018, April 04). Interventions That May Slow Memory Loss in Early Alzheimer’s Disease. Retrieved February 1, 2019, from https://www.alzheimers.net/interventions-may-slow-memory-loss-in-early-alzheimers/
Duan, Y., Lu, L., Chen, J., Wu, C., Liang, J., Zheng, Y., … & Tang, C. (2018). Psychosocial interventions for Alzheimer’s disease cognitive symptoms: a Bayesian network meta-analysis. BMC Geriatrics, 18(1), 175.
Fazio, S., Pace, D., Flinner, J., & Kallmyer, B. (2018). The fundamentals of person-centered care for individuals with dementia. The Gerontologist, 58(suppl_1), S10-S19.
Graham, W. V., Bonito-Oliva, A., & Sakmar, T. P. (2017). Update on Alzheimer’s disease therapy and prevention strategies. Annual review of medicine, 68, 413-430.
Interventions Pharmacological and Non-Pharmacological Interventions. (n.d.). Retrieved February 1, 2019, from http://dementia.ie/information/interventions
Kales, H. C., Lyketsos, C. G., Miller, E. M., & Ballard, C. (2018). Management of behavioral and psychological symptoms in people with Alzheimer’s disease: an international Delphi consensus. International Psychogeriatrics, 1-8.
Mayo Clinic Staff. (2018, December 08). Alzheimer’s disease. Retrieved February 1, 2019, from https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447
Napoletan, A. (2017, April 21). 6 Online Alzheimer’s Resources You Shouldn’t Be Without. Retrieved February 1, 2019, from https://www.alzheimers.net/2013-05-03/alzheimers-resources/
Porteri, C., Albanese, E., Scerri, C., Carrillo, M. C., Snyder, H. M., Martensson, B., … & Frisoni, G. B. (2017). The biomarker-based diagnosis of Alzheimer’s disease. 1—ethical and societal issues. Neurobiology of aging, 52, 132-140.
Preston, J., McTeigue, J., Opperman, C., Krieg, J. D. S., Brandt-Fontaine, M., Yasis, A., & Shen, F. X. (2016). The legal implications of detecting Alzheimer’s disease earlier. AMA journal of ethics, 18(12), 1207.